דנמרק - דנית - Lægemiddelstyrelsen (Danish Medicines Agency)

ceva santé animale - paracetamol - opløsning til anvendelse i drikkevand - 400 mg/ml - svin

האיחוד האירופי - דנית - EMA (European Medicines Agency)

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

דנמרק - דנית - Lægemiddelstyrelsen (Danish Medicines Agency)

lavet pharmaceuticals ltd. - doxycyclinhyclat - granulat til oral opløsning - 500 mg/g - fjerkræ, svin

האיחוד האירופי - דנית - EMA (European Medicines Agency)

viatris limited - clopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevation akut myokardieinfarkt, i kombination med asa i medicinsk behandlede patienter, der er berettiget til trombolytisk terapi. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. for yderligere oplysninger henvises der til afsnit 5.

האיחוד האירופי - דנית - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrelhydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiske midler - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

דנמרק - דנית - Lægemiddelstyrelsen (Danish Medicines Agency)

ceva-phylaxia co. ltd. - aviær infektiøs bursitis virus, stamme syza-26 (levende, svækket), hønsekød - koncentrat og solvens til injektionsvæske, suspension

דנמרק - דנית - Lægemiddelstyrelsen (Danish Medicines Agency)

ceva-phylaxia co. ltd. - aviær infektiøs bursitis disease virus, stammevmg 91 (levende) - koncentrat og solvens til injektionsvæske, suspension

האיחוד האירופי - דנית - EMA (European Medicines Agency)

dr. friedrich eberth arzneimittel gmbh - lasofoxifene tartrat - osteoporose, postmenopausale - køn hormoner og modulatorer af den genitale system, - fablyn er indiceret til behandling af osteoporose hos postmenopausale kvinder med øget risiko for fraktur. der er vist en signifikant reduktion i forekomsten af ​​vertebrale og ikke-vertebrale frakturer, men ikke hoftefrakturer (se afsnit 5. når du bestemme valg af fablyn eller andre behandlingsformer, herunder østrogener, til postmenopausale kvinde, bør det overvejes, menopausale symptomer, effekter på livmoder og bryst væv, og hjerte-kar-risici og fordele (se afsnit 5.

דנמרק - דנית - Lægemiddelstyrelsen (Danish Medicines Agency)

aspen pharma trading limited - melphalan - filmovertrukne tabletter - 2 mg

דנמרק - דנית - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - melphalan - filmovertrukne tabletter - 2 mg